Related Experiment Video
Updated: Jan 20, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
Association of Socioeconomic Position, Prostate-specific Antigen, and Age with Observation in Low-risk Prostate
Thomas Paul Scherer1, Dominik Menges2,3, Uwe Bieri1,4
1Department of Urology, University Hospital Zurich (USZ), University of Zurich (UZH), Zurich, Switzerland.
Background And Objective:
Observation remains the recommended management approach for low-risk prostate cancer (PCa), aiming to balance oncological control and avoidance of overtreatment. This study investigated the use of observation and its association with patients' socioeconomic position (SEP), age, and prostate-specific antigen (PSA) level on treatment choice in Switzerland.
Methods:
This cohort study analyzed Gleason score 6 PCa diagnoses in 2020 and 2021 from the Swiss National Agency for Cancer Registration dataset. Variables included age, PSA value, residence, and treatment codes. Municipality-based SEP deciles were linked to patients. Multivariable regression assessed the associations between SEP and observational management.
Key Findings And Limitations:
Of 4296 men, 2876 (65.4%) received observational management, 792 (18.0%) underwent active treatment, and management was unknown in 728 (16.6%). Compared with men from low SEP areas, those from middle (odds ratio [OR] 1.11, 95% confidence interval [CI]: 0.92-1.35) and high SEP (OR 1.29, 95% CI: 1.06-1.58) areas had higher odds of observation. Men aged 60-70 yr (OR 1.53, 95% CI: 1.24-1.89) and >70 yr (OR 2.10, 95% CI: 1.68-2.62) were more likely to undergo observation than those aged <60 yr. PSA 5-10 ng/ml (OR 0.67, 95% CI: 0.55-0.82) and >10 ng/ml (OR 0.60, 95% CI: 0.46-0.78) were associated with lower odds of observation compared with PSA <5 ng/ml.
Conclusions And Clinical Implications:
Most men diagnosed with localized low-risk PCa in Switzerland underwent observational management as the primary strategy in 2020 and 2021. However, at least 18% of men still received active treatment. Lower SEP, younger age, and higher PSA values were risk factors for active treatment within low-risk PCa patients.
Patient Summary:
We looked at how men in Switzerland with low-risk prostate cancer were treated in 2020 and 2021. We found that most men chose observation instead of immediate treatment, but men with lower socioeconomic position, younger age, or higher prostate-specific antigen levels were more likely to have active treatment. This suggests that there are opportunities to reduce unnecessary treatment for certain patient groups.
Related Concept Videos
05:19A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
08:03Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells
11:07Focal Laser Ablation of Prostate Cancer: An Office Procedure
05:07Intra-prostatic Injection of Cancer Cells: A Technique to Deliver Cancer Cells for Establishing Orthotopic Prostate Cancer Mouse Model
07:16Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
11:29miRNA Expression Analyses in Prostate Cancer Clinical Tissues